The Peter Attia Drive

The Peter Attia Drive

#320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape

Oct 7, 2024 · 20:36

Listen to Episode

✨ AI Summary

Peter discusses new insights on GLP-1 agonists like Ozempic and Wegovy.
Efficacy, side effects, and impact on body composition are examined.
Resistance training's interaction with weight-loss drugs and future drugs are explored.

Guests on This Episode

ME

Mounjaro) - efficacy

1 podcast appearance

More from The Peter Attia Drive

#385 - AMA #82: Applying the tools of longevity in the real world: disease prevention, DEXA scans, artificial sweeteners, injury recovery, stability training, habit formation, protein intake and mTOR activation, and more

Mar 23, 2026 · 18:52

#384 - Special episode — Obicetrapib: The CETP inhibitor with cardiovascular benefits and potential Alzheimer's prevention

Mar 16, 2026 · 52:40

#381 ‒ Alzheimer's disease in women: how hormonal transitions impact the female brain, the role of HRT, genetics, and lifestyle on risk, and emerging diagnostics and therapies | Lisa Mosconi, Ph.D.

Jan 26, 2026 · 02:06:34

#380 ‒ The seed oil debate: are they uniquely harmful relative to other dietary fats? | Layne Norton, Ph.D.

Jan 19, 2026 · 02:07:42

View all episodes →